We evaluated the number of RGCs in both experimental groups at the end of the experimental period using immunohistochemistry with an antibody against Brn3a (
Fig. 2). The number of ganglion cells per mm of retina was significantly (46%) lower in HYA-treated eyes than in control eyes (control: 30.6 ± 1.2 ganglion cells/mm, HYA-treated: 16.6 ± 1.0 ganglion cells/mm. ANOVA, Bonferroni's test,
P < 0.001, n = 7 in both groups;
Figs. 2A,
2B,
2E). We also analyzed a specific subtype of RGCs, ooDSGCs, which express the neuropeptide CART.
42,43 Immunohistochemistry analysis showed that CART labeling was poorer within the ganglion cell layer of HYA-treated eyes than of control eyes (
Figs. 2C,
2D). Quantification of CART-positive RGCs (
Fig. 2F) versus those lacking this marker (
Fig. 2G) showed a greater loss of ooDSGCs over other RGCs in HYA-injected eyes than in control eyes. Specifically, the number of ooDSGCs per mm of retina was significantly lower (56%) in HYA-treated eyes than in control eyes (control: 12.4 ± 1.1 CART
+Brn3a
+/mm, HYA-treated: 5.5 ± 0.7 CART
+Brn3a
+/mm, ANOVA, Bonferroni's test,
P < 0.001, n = 7 in both groups;
Fig. 2F). This contrasted with the 39% reduction in the number of CART-negative RGCs per mm of retina in HYA-treated eyes relative to control eyes (control: 18.2 ± 0.4 CART
−Brn3a
+/mm, HYA-treated: 11.1 ± 0.3 CART
−Brn3a
+/mm, ANOVA, Bonferroni's test,
P < 0.001, n = 7 in both groups;
Fig. 2G). These results indicate that ooDSGCs are more susceptible than other RGCs to serial HYA-treatment.